

Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers

Horizon Europe

CODE	SCOPE
HORIZON-MISS-2026-02-CANCER-03	International
LOCATION	STATUS
Europe	Open
PROGRAM	CURATED BY
Horizon Europe	Maria Macedo
GENERATED AT	
June 8, 2026	

Financial Details

SUPPORT TYPE	MAXIMUM FUNDING RATE
Non-Refundable	100%
BUDGET	ELIGIBLE PROJECT VALUE
22.2M€	Up to 8M€
MAXIMUM DURATION	
60 months	

Dates & Deadlines

PUBLICATION DATE

Not defined

OPENING DATE

February 10, 2026

Application Phases

- Deadline: September 15, 2026 at 04:00 PM (100 days left)

Objectives

Objectives

This incentive is part of the Horizon Europe framework and is aligned with missions focusing on cancer research and related innovations. It aims to support eligible organizations across Europe, including research institutions, universities, public and private entities, and consortia that can deliver solutions advancing the fight against cancer. The incentive targets advancements in prevention, diagnosis, treatment, and patient care by fostering collaboration at the European level. Eligible companies are those that can demonstrate expertise and the capacity to contribute to impactful R&I in the oncology field and support the objectives outlined by Horizon Europe and the EU's Cancer Mission.

Funding

The funding from Horizon Europe is generally provided as non-refundable grants. The maximum funding rate for eligible entities under Horizon Europe Research and Innovation Actions can reach up to 100% for non-profit entities and 70% for commercial entities, including indirect costs calculated at a flat rate. Budget limits and minimum or maximum project values are defined by the specific topic and work programme, with typical EU contribution guidelines provided for each call. The total call budget and upper/lower project amounts will be provided in the Work Programme or topic description on the Funding & Tenders Portal. Applicants should carefully consult these documents to determine the eligibility of their cost structures and financial needs.

Eligible Expenses

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs

Eligibility

Eligible Sectors

- Health & Life Sciences

Company Sizes

- Micro
- Sme

- Small Mid-Cap
- Mid-Cap
- Large
- Private non-profit entities
- Public entities

Application Mode

- Consortium / Copromotion

EU Programme Details

CALL ID	EXPECTED PROJECTS
HORIZON-MISS-2026-02-CANCER-03	3

Official Links

Official Regulation:

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2026-02-CANCER-03?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&isExactMatch=true&status=31094501,31094502&programmePart=43108557&frameworkProgramme=43108390&deadlineDate=1780182000000,1798675200000>

Grantavia page: <https://grantavia.com/en/incentives/pragmatic-clinical-trials-to-optimise-immunotherapeutic-interventions-for-patients-with-refractory-cancers>

Schedule a meeting: <https://calendly.com/ines-carreira-fi-group/reuniao>